BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to treat...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

Canbridge raised $98 million in a series D round to build out its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge also intends to solidify its rare disease...
BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP) caused...
BioCentury | May 16, 2019
Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
BioCentury | Apr 19, 2019
Company News

ImmunoForge gets rights to PB1023 from PhaseBio

PhaseBio granted ImmunoForge exclusive, worldwide rights to develop and commercialize PB1023 for all indications except diabetes, obesity and non-alcoholic steatohepatitis (NASH). ImmunoForge Co. Ltd. (Seoul, South Korea) will develop the compound for serious sarcopenia-related diseases....
BioCentury | Apr 5, 2019
Company News

Pierre Fabre gets European, African rights to Puma's Nerlynx

Pierre Fabre will pay $60 million up front for commercialization rights to Puma's Nerlynx neratinib in Europe, excluding Russia and Ukraine, and in certain North and West African countries. Puma Biotechnology Inc. (NASDAQ:PBYI) is also...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Puma falls on Nerlynx sales miss; cabozantinib sales lift Exelixis

Puma Biotechnology Inc. (NASDAQ:PBYI) shares tumbled, while Exelixis Inc. (NASDAQ:EXEL) gained after the companies reported 3Q18 financial results for their flagship therapies. Puma lost $18.53 (48%) to $20.07 on Nov. 2 after the company said...
BioCentury | Nov 2, 2018
Company News

Earnings roundup: Puma falls on Nerlynx sales miss; cabozantinib sales lift Exelixis

Puma Biotechnology Inc. (NASDAQ:PBYI) shares tumbled, while Exelixis Inc. (NASDAQ:EXEL) gained after the companies reported 3Q18 financial results for their flagship therapies. Puma lost $18.53 (48%) to $20.07 Friday after the company said the discontinuation...
Items per page:
1 - 10 of 155